These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 715450)

  • 1. Memory impairment in Korsakoff's psychosis: a correlation with brain noradrenergic activity.
    McEntee WJ; Mair RG
    Science; 1978 Nov; 202(4370):905-7. PubMed ID: 715450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoamine activity correlates with psychometric deficits in Korsakoff's disease.
    Mair RG; McEntee WJ; Zatorre RJ
    Behav Brain Res; 1985 May; 15(3):247-54. PubMed ID: 2408635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurochemical pathology in Korsakoff's psychosis: implications for other cognitive disorders.
    McEntee WJ; Mair RG; Langlais PJ
    Neurology; 1984 May; 34(5):648-52. PubMed ID: 6200802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Central nervous system catecholamine metabolism in Korsakoff's psychosis.
    Martin PR; Weingartner H; Gordon EK; Burns RS; Linnoila M; Kopin IJ; Ebert MH
    Ann Neurol; 1984 Feb; 15(2):184-7. PubMed ID: 6200058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multimodal sensory discrimination deficits in Korsakoff's psychosis.
    Mair RG; Doty RL; Kelly KM; Wilson CS; Langlais PJ; McEntee WJ; Vollmecke TA
    Neuropsychologia; 1986; 24(6):831-9. PubMed ID: 2433640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Korsakoff's psychosis: noradrenergic systems and cognitive impairment.
    Mair RG; McEntee WJ
    Behav Brain Res; 1983 Jul; 9(1):1-32. PubMed ID: 6136282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced concentrations of arginine vasopressin and MHPG in lumbar CSF of patients with Korsakoff's psychosis.
    Mair RG; Langlais PJ; Mazurek MF; Beal MF; Martin JB; McEntee WJ
    Life Sci; 1986 Jun; 38(25):2301-6. PubMed ID: 2425205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concentration gradients of monoamine metabolites in human cerebrospinal fluid.
    Sjöström R; Ekstedt J; Anggård E
    J Neurol Neurosurg Psychiatry; 1975 Jul; 38(7):666-8. PubMed ID: 1159438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurochemical specificity of learning: dopamine and motor learning.
    McEntee WJ; Mair RG; Langlais PJ
    Yale J Biol Med; 1987; 60(2):187-93. PubMed ID: 2437709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Central noradrenergic function in man: vanillylmandelic acid in CSF.
    Jimerson DC; Gordon EK; Post RM; Goodwin FK
    Brain Res; 1975 Dec; 99(2):434-9. PubMed ID: 1182564
    [No Abstract]   [Full Text] [Related]  

  • 11. Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state.
    Fujimoto A; Nagao T; Ebara T; Sato M; Otsuki S
    Biol Psychiatry; 1983 Oct; 18(10):1141-52. PubMed ID: 6197099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Origins of catecholamine metabolites in monkey cerebrospinal fluid.
    Gordon E; Perlow M; Oliver J; Ebert M; Kopin I
    J Neurochem; 1975 Sep; 25(3):347-9. PubMed ID: 808591
    [No Abstract]   [Full Text] [Related]  

  • 13. The circadian pattern of catcholamine metabolites and cAMP in the cerebrospinal fluid of subhuman primates.
    Perlow M; Gordon E; Ebert M; Festoff B; Chase TN
    Trans Am Neurol Assoc; 1976; 101():279-80. PubMed ID: 195383
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of the alpha 2-antagonist idazoxan on monoaminergic parameters measured in the cerebrospinal fluid of rabbits.
    Dillen L; Claeys M; De Potter WP
    Eur J Pharmacol; 1987 May; 137(1):33-40. PubMed ID: 2440704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF monoamine metabolites in mania.
    Swann AC; Secunda S; Davis JM; Robins E; Hanin I; Koslow SH; Maas JW
    Am J Psychiatry; 1983 Apr; 140(4):396-400. PubMed ID: 6188381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced lumbar CSF somatostatin levels in Alzheimer's disease.
    Wood PL; Etienne P; Lal S; Gauthier S; Cajal S; Nair NP
    Life Sci; 1982 Nov; 31(19):2073-9. PubMed ID: 6184590
    [No Abstract]   [Full Text] [Related]  

  • 17. Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies.
    Garelis E; Young SN; Lal S; Sourkes TL
    Brain Res; 1974 Oct; 79(1):1-8. PubMed ID: 4279131
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer's dementia.
    Palmer AM; Sims NR; Bowen DM; Neary D; Palo J; Wikstrom J; Davison AN
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):481-4. PubMed ID: 6204017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism.
    Stern Y; Mayeux R; Côté L
    Arch Neurol; 1984 Oct; 41(10):1086-9. PubMed ID: 6206831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Childhood psychosis and monoamine metabolites in spinal fluid.
    Gillberg C; Svennerholm L; Hamilton-Hellberg C
    J Autism Dev Disord; 1983 Dec; 13(4):383-96. PubMed ID: 6198318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.